Additional Genome Editing Nuclease: BRAIN-Metagenome-Cas 01 (BMC01)

8 December 2021, Zwingenberg (Germany) - BRAIN Biotech AG has successfully extended its proprietary genome editing toolbox with the addition of BRAIN-Metagenome-Cas 01 (BMC01) nuclease. The company aims to develop a genome editing platform with significant economic and scientific potential. The BMC01 nuclease complements the BRAIN-Engineered Cas (BEC) which has been announced to the public in May, 2021.